Territorial Availability: Available through Bertin Technologies only in France
- Synonyms
- 2-(acetyloxy)-4-(trifluoromethyl)-benzoic acid
- Correlated keywords
- 2087491-29-8 B-2 F-1? F1-? OX6 TX-B2 TXB-2 UR1501
- Product Overview:
Triflusal is an inhibitor of platelet aggregation (IC50s = 48.3 and 693 µM in isolated human whole blood and platelet-rich plasma, respectively).{52661} It inhibits production of thromboxane B2 (TXB2; Item No. 19030) and 6 keto prostaglandin F1? (6-keto-PGF1?; Item No. 15210) induced by arachidonic acid (Item Nos. 90010 | 90010.1 | 10006607) with IC50 values of 468 and 339 µM, respectively, in isolated human whole blood. Triflusal decreases IgG-ovalbumin immune complex-induced NF-?B nuclear translocation and production of nitric oxide (NO) in isolated rat peritoneal macrophages when used at a concentration of 1,000 µM.{8312} Oral administration of triflusal (30 mg/kg) reduces infarct volume and peri-infarct levels of OX-6, a marker of activated microglia, in a rat model of focal ischemia induced by permanent middle cerebral artery occlusion (MCAO).{52662} It also reduces increases in cortical amyloid-? precursor protein (APP) levels induced by intracerebroventricular administration of amyloid-? (25-35) in rats at the same dose.{52663}
Cayman Chemical’s mission is to help make research possible by supplying scientists worldwide with the basic research tools necessary for advancing human and animal health. Our utmost commitment to healthcare researchers is to offer the highest quality products with an affordable pricing policy.
Our scientists are experts in the synthesis, purification, and characterization of biochemicals ranging from small drug-like heterocycles to complex biolipids, fatty acids, and many others. We are also highly skilled in all aspects of assay and antibody development, protein expression, crystallization, and structure determination.
Over the past thirty years, Cayman developed a deep knowledge base in lipid biochemistry, including research involving the arachidonic acid cascade, inositol phosphates, and cannabinoids. This knowledge enabled the production of reagents of exceptional quality for cancer, oxidative injury, epigenetics, neuroscience, inflammation, metabolism, and many additional lines of research.
Our organic and analytical chemists specialize in the rapid development of manufacturing processes and analytical methods to carry out clinical and commercial GMP-API production. Pre-clinical drug discovery efforts are currently underway in the areas of bone restoration and repair, muscular dystrophy, oncology, and inflammation. A separate group of Ph.D.-level scientists are dedicated to offering Hit-to-Lead Discovery and Profiling Services for epigenetic targets. Our knowledgeable chemists can be contracted to perform complete sample analysis for analytes measured by the majority of our assays. We also offer a wide range of analytical services using LC-MS/MS, HPLC, GC, and many other techniques.
Accreditations
ISO/IEC 17025:2005
ISO Guide 34:2009
Cayman is a leader in the field of emerging drugs of abuse, providing high-purity Schedule I-V Controlled Substances to federally-licensed laboratories and qualified academic research institutions for forensic analyses. We are certified by ACLASS Accreditation Services with dual accreditation to ISO/IEC 17025:2005 and ISO Guide 34:2009.